TrialThe Lancet. Respiratory medicine2017

Vandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial.

Kiyotaka Yoh et al.PubMed ↗Publisher ↗

No numbers read from the abstract.